Related Experiment Video

Updated: Aug 16, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Precious Gene: The Application of RET-Altered Inhibitors

Qitao Gou1, Xiaochuan Gan1, Longhao Li1

  • 1Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong, Chongqing 400016, China.

Molecules (Basel, Switzerland)
|December 23, 2022
PubMed

Insights

Novel RET inhibitors offer targeted therapy for cancers like lung and thyroid cancer, overcoming limitations of older drugs. These new treatments show promise for improved efficacy and safety in patients with RET alterations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The proto-oncogene rearrangement during transfection (RET) is implicated in various cancers, including lung and thyroid cancer.
  • Current multikinase inhibitors (MKIs) for RET-altered cancers face challenges due to off-target effects, leading to drug resistance and adverse events.
  • There is a critical need for more effective and specific therapeutic strategies for RET-driven malignancies.

Purpose of the Study:

  • To review the current landscape of therapeutics targeting RET alterations.
  • To highlight the efficacy and safety profiles of novel, highly potent, and RET-specific inhibitors.
  • To discuss the clinical potential of emerging agents like selpercatinib, pralsetinib, TPX-0046, and zetletinib.

Main Methods:

  • Literature review of preclinical and clinical studies on RET inhibitors.
  • Analysis of data regarding the efficacy and safety of novel RET-specific agents.
  • Comparison of novel inhibitors with existing MKIs in the context of RET-altered cancers.

Main Results:

  • Novel RET inhibitors, including selpercatinib and pralsetinib, demonstrate high potency and specificity.
  • These agents are associated with improved tolerability and reduced off-target effects compared to traditional MKIs.
  • Ongoing clinical trials for TPX-0046 and zetletinib suggest promising therapeutic potential.

Conclusions:

  • Novel RET inhibitors represent a significant advancement in treating RET-altered cancers.
  • These targeted therapies offer a more effective and safer treatment paradigm for patients with specific genetic alterations.
  • Further clinical investigation will solidify the role of these agents in precision oncology for RET-driven tumors.
Keywords:
RET-selective inhibitorTPX-0046molecular target therapypralsetinibselpercatinibsmall molecule inhibitortyrosine kinase inhibitorzetletinib

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.4K
RNA Catalyst as a Reporter for Screening Drugs against RNA Editing in Trypanosomes09:19

RNA Catalyst as a Reporter for Screening Drugs against RNA Editing in Trypanosomes

Published on: July 22, 2014

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K